2
|
Brinson RG, Marino JP, Delaglio F, Arbogast LW, Evans RM, Kearsley A, Gingras G, Ghasriani H, Aubin Y, Pierens GK, Jia X, Mobli M, Grant HG, Keizer DW, Schweimer K, Ståhle J, Widmalm G, Zartler ER, Lawrence CW, Reardon PN, Cort JR, Xu P, Ni F, Yanaka S, Kato K, Parnham SR, Tsao D, Blomgren A, Rundlöf T, Trieloff N, Schmieder P, Ross A, Skidmore K, Chen K, Keire D, Freedberg DI, Suter-Stahel T, Wider G, Ilc G, Plavec J, Bradley SA, Baldisseri DM, Sforça ML, Zeri ACDM, Wei JY, Szabo CM, Amezcua CA, Jordan JB, Wikström M. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics. MAbs 2018; 11:94-105. [PMID: 30570405 PMCID: PMC6343768 DOI: 10.1080/19420862.2018.1544454] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
The increased interest in using monoclonal antibodies (mAbs) as a platform for biopharmaceuticals has led to the need for new analytical techniques that can precisely assess physicochemical properties of these large and very complex drugs for the purpose of correctly identifying quality attributes (QA). One QA, higher order structure (HOS), is unique to biopharmaceuticals and essential for establishing consistency in biopharmaceutical manufacturing, detecting process-related variations from manufacturing changes and establishing comparability between biologic products. To address this measurement challenge, two-dimensional nuclear magnetic resonance spectroscopy (2D-NMR) methods were introduced that allow for the precise atomic-level comparison of the HOS between two proteins, including mAbs. Here, an inter-laboratory comparison involving 26 industrial, government and academic laboratories worldwide was performed as a benchmark using the NISTmAb, from the National Institute of Standards and Technology (NIST), to facilitate the translation of the 2D-NMR method into routine use for biopharmaceutical product development. Two-dimensional 1H,15N and 1H,13C NMR spectra were acquired with harmonized experimental protocols on the unlabeled Fab domain and a uniformly enriched-15N, 20%-13C-enriched system suitability sample derived from the NISTmAb. Chemometric analyses from over 400 spectral maps acquired on 39 different NMR spectrometers ranging from 500 MHz to 900 MHz demonstrate spectral fingerprints that are fit-for-purpose for the assessment of HOS. The 2D-NMR method is shown to provide the measurement reliability needed to move the technique from an emerging technology to a harmonized, routine measurement that can be generally applied with great confidence to high precision assessments of the HOS of mAb-based biotherapeutics.
Collapse
Affiliation(s)
- Robert G Brinson
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - John P Marino
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Frank Delaglio
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Luke W Arbogast
- a Institute of Bioscience and Biotechnology Research , National Institute of Standards and Technology and the University of Maryland , Rockville , MD , USA
| | - Ryan M Evans
- b Applied and Computational Mathematics Division , National Institute of Standards and Technology , Gaithersburg , MD , USA
| | - Anthony Kearsley
- b Applied and Computational Mathematics Division , National Institute of Standards and Technology , Gaithersburg , MD , USA
| | - Geneviève Gingras
- c Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , Ottawa , ON , Canada
| | - Houman Ghasriani
- c Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , Ottawa , ON , Canada
| | - Yves Aubin
- c Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate , Health Canada , Ottawa , ON , Canada
| | - Gregory K Pierens
- d The Centre for Advanced Imaging , The University of Queensland , St Lucia , QLD , Australia
| | - Xinying Jia
- d The Centre for Advanced Imaging , The University of Queensland , St Lucia , QLD , Australia
| | - Mehdi Mobli
- d The Centre for Advanced Imaging , The University of Queensland , St Lucia , QLD , Australia
| | - Hamish G Grant
- e Bio21 Molecular Science & Biotechnology Institute , The University of Melbourne , Victoria , Australia
| | - David W Keizer
- e Bio21 Molecular Science & Biotechnology Institute , The University of Melbourne , Victoria , Australia
| | | | - Jonas Ståhle
- g Department of Organic Chemistry , Arrhenius Laboratory, Stockholm University , Stockholm , Sweden
| | - Göran Widmalm
- g Department of Organic Chemistry , Arrhenius Laboratory, Stockholm University , Stockholm , Sweden
| | - Edward R Zartler
- h Analytical R&D , Pfizer Essential Health , Lake Forest , IL , USA
| | - Chad W Lawrence
- i Pacific Northwest National Laboratory , Earth and Biological Sciences Directorate , Richland , DC , USA
| | - Patrick N Reardon
- i Pacific Northwest National Laboratory , Earth and Biological Sciences Directorate , Richland , DC , USA
| | - John R Cort
- i Pacific Northwest National Laboratory , Earth and Biological Sciences Directorate , Richland , DC , USA
| | - Ping Xu
- j Department of Downstream Processing and Analytics , Human Health Therapeutics Research Centre, National Research Council of Canada , Montreal , Quebec , Canada
| | - Feng Ni
- j Department of Downstream Processing and Analytics , Human Health Therapeutics Research Centre, National Research Council of Canada , Montreal , Quebec , Canada
| | - Saeko Yanaka
- k Institute for Molecular Science and Exploratory Research Center on Life and Living Systems , National Institutes of Natural Sciences , Myodaiji, Okazaki , Japan
| | - Koichi Kato
- k Institute for Molecular Science and Exploratory Research Center on Life and Living Systems , National Institutes of Natural Sciences , Myodaiji, Okazaki , Japan
| | - Stuart R Parnham
- l Department of Biochemistry and Molecular Biology , Medical University of South Carolina , Charleston , SC , USA
| | - Desiree Tsao
- m Analytical Development , Momenta Pharmaceuticals , Cambridge , MA , USA
| | - Andreas Blomgren
- n Laboratory Unit , Swedish Medical Products Agency, Laboratory , Uppsala , Sweden
| | - Torgny Rundlöf
- n Laboratory Unit , Swedish Medical Products Agency, Laboratory , Uppsala , Sweden
| | - Nils Trieloff
- o NMR-supported Structural Biology , Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) , Berlin , Germany
| | - Peter Schmieder
- o NMR-supported Structural Biology , Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) , Berlin , Germany
| | - Alfred Ross
- p Roche Pharmaceutical Research & Early Development , Pre-Clinical CMC, Roche Innovation Center Basel , Basel , Switzerland
| | - Ken Skidmore
- q Analytical Operations , Genentech , South San Francisco , CA , USA
| | - Kang Chen
- r Center for Drug Evaluation and Research , Food and Drug Administration , Maryland , USA
| | - David Keire
- r Center for Drug Evaluation and Research , Food and Drug Administration , Maryland , USA
| | - Darón I Freedberg
- s Center for Biologics Evaluation and Research , Food and Drug Administration , Maryland , USA
| | - Thea Suter-Stahel
- t Department of Biology , Institute of Molecular Biology and Biophysics , ETH Zurich, Zurich , Switzerland
| | - Gerhard Wider
- t Department of Biology , Institute of Molecular Biology and Biophysics , ETH Zurich, Zurich , Switzerland
| | - Gregor Ilc
- u NMR Centre , EN-FIST Centre of Excellence , Ljubljana , Slovenia.,v NMR Centre , National Institute of Chemistry , Ljubljana , Slovenia
| | - Janez Plavec
- u NMR Centre , EN-FIST Centre of Excellence , Ljubljana , Slovenia.,v NMR Centre , National Institute of Chemistry , Ljubljana , Slovenia
| | - Scott A Bradley
- w Eli Lilly and Company , Lilly Corporate Center , Indianapolis , IN , USA
| | - Donna M Baldisseri
- x MRS - Application Science , Bruker BioSpin Corporation , Billerica , MA , USA
| | - Mauricio Luis Sforça
- y Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM) , Campinas, Brazil
| | - Ana Carolina de Mattos Zeri
- z Brazilian Synchrotron Light Laboratory (LNLS), Brazilian Center for Research in Energy and Materials (CNPEM) , Campinas, Brazil , CEP
| | - Julie Yu Wei
- aa Protein Product Development , Biogen Inc ., Cambridge , MA , USA
| | - Christina M Szabo
- ab Baxter Pharmaceuticals R&D , Baxter Healthcare , Round Lake, IL , USA
| | - Carlos A Amezcua
- ab Baxter Pharmaceuticals R&D , Baxter Healthcare , Round Lake, IL , USA
| | - John B Jordan
- ac Global Regulatory and R&D Policy , Amgen Inc ., Thousand Oaks , CA , USA
| | - Mats Wikström
- ad Higher Order Structure, Attribute Sciences , Amgen Inc ., Thousand Oaks , CA , USA
| |
Collapse
|
3
|
Li C, Bhavaraju S, Thibeault MP, Melanson J, Blomgren A, Rundlöf T, Kilpatrick E, Swann CJ, Rudd T, Aubin Y, Grant K, Butt M, Shum W, Kerim T, Sherwin W, Nakagawa Y, Pavón S, Arrastia S, Weel T, Pola A, Chalasani D, Walfish S, Atouf F. Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocin. J Pharm Biomed Anal 2018; 166:105-112. [PMID: 30640042 DOI: 10.1016/j.jpba.2018.12.028] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 12/17/2018] [Accepted: 12/18/2018] [Indexed: 02/07/2023]
Abstract
USP's peptide reference standards content is typically determined using an HPLC assay against an external standard for which the purity was determined by a mass balance approach. To explore the use of other analytical methods, the USP Biologics Department conducted a multi-laboratory collaborative study. The study determined the inter-laboratory variability for peptide quantitation using the following methods: HPLC assay, quantitative nuclear magnetic resonance (qNMR) spectroscopy, or amino acid analysis (AAA). The three methods were compared with regard to their suitability for quantitation of the nonapeptide oxytocin. In this study, the HPLC assay method using the same peptide bulk material as the standard showed the lowest inter-lab variability. The coefficient of variation (%CV) was calculated without counting the uncertainty associated with the purity assignment of the standard with mass balance. The proton qNMR method is a direct measurement of the peptide against an internal standard, which is not difficult to perform under common laboratory conditions. Because of the simpler operation and shorter analytical time, qNMR as a primary method for peptide reference standard value assignment deserves further exploration.
Collapse
Affiliation(s)
- Chensheng Li
- United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, United States
| | - Sitaram Bhavaraju
- United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, United States
| | - Marie-Pier Thibeault
- National Research Council Canada (NRC), 1200 Montreal Road, Ottawa, ON K1A 0R6, Canada
| | - Jeremy Melanson
- National Research Council Canada (NRC), 1200 Montreal Road, Ottawa, ON K1A 0R6, Canada
| | - Andreas Blomgren
- Swedish Medical Products Agency (Lakemedelsverket), Uppsala Science Park, Dag Hammarskjölds väg 42, 75237 Uppsala, Sweden
| | - Torgny Rundlöf
- Swedish Medical Products Agency (Lakemedelsverket), Uppsala Science Park, Dag Hammarskjölds väg 42, 75237 Uppsala, Sweden
| | - Eric Kilpatrick
- National Institute of Standards and Technology (NIST), 100 Bureau Dr, Stop 8314, Gaithersburg, MD 20899, United States
| | - Carolyn J Swann
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, Potters Bar, United Kingdom
| | - Timothy Rudd
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, Potters Bar, United Kingdom
| | - Yves Aubin
- Centre for Vaccine Evaluation, Health Canada, 251 Sir Frederick Banting, A.L. 2201E, Tunney's Pasture, Ottawa, ON K1A 0K9, Canada
| | - Kevin Grant
- Australian Therapeutic Goods Administration (TGA), 136 Narrabundah Lane, SYMONSTON, Australian Capital Territory (ACT) 2609, Australia
| | - Margaret Butt
- Australian Therapeutic Goods Administration (TGA), 136 Narrabundah Lane, SYMONSTON, Australian Capital Territory (ACT) 2609, Australia
| | - WaiKei Shum
- Australian Therapeutic Goods Administration (TGA), 136 Narrabundah Lane, SYMONSTON, Australian Capital Territory (ACT) 2609, Australia
| | - Tursun Kerim
- Australian Therapeutic Goods Administration (TGA), 136 Narrabundah Lane, SYMONSTON, Australian Capital Territory (ACT) 2609, Australia
| | - William Sherwin
- Australian Therapeutic Goods Administration (TGA), 136 Narrabundah Lane, SYMONSTON, Australian Capital Territory (ACT) 2609, Australia
| | - Yukari Nakagawa
- Pharmaceutical and Medical Device Regulatory Science Society of Japan (PMRJ), Japanese Pharmacopoeia Reference Standards Laboratory (JPRS Lab), 2-1-2, Hiranomachi, Chuo-ku, Osaka 541-0046, Japan
| | - Sergi Pavón
- BCN Peptides, Poligon Industrial Els Vinyets Els Fogars, Sant Quinti de Mediona, Catalonia 08777, Spain
| | - Silvia Arrastia
- BCN Peptides, Poligon Industrial Els Vinyets Els Fogars, Sant Quinti de Mediona, Catalonia 08777, Spain
| | - Tim Weel
- Aspen Oss BV, Corellistraat 10, 5344 AG Oss, PO Box 98, 5340 AB Oss, Netherlands
| | - Arunima Pola
- United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, United States
| | - Dinesh Chalasani
- United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, United States
| | - Steven Walfish
- United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, United States
| | - Fouad Atouf
- United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, United States.
| |
Collapse
|
5
|
Charles BG, Blomgren A, Nasveld PE, Kitchener SJ, Jensen A, Gregory RM, Robertson B, Harris IE, Reid MP, Edstein MD. Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. Eur J Clin Pharmacol 2007; 63:271-8. [PMID: 17216435 DOI: 10.1007/s00228-006-0247-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2006] [Accepted: 11/29/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVE The purpose of this study was to determine the population pharmacokinetics of mefloquine in healthy military personnel during prophylaxis for malaria infections. METHODS The subjects were 1,111 Australian soldiers participating in two studies: a randomised double-blinded study (group A, 161 subjects) and an open-label study (group B, 950 subjects). Following a loading dose (250 mg mefloquine base daily, 3 days), subjects received an oral weekly maintenance dose of 250 mg over 6 months. Blood was collected after the last split loading dose then at weeks 4, 8 and 16 for group A, and at weeks 13 and 26 for group B. Plasma mefloquine concentrations were measured by high-performance liquid chromatography (HPLC). Pharmacokinetic modelling was performed using NONMEM. RESULTS A two-compartment model with inter-occasion variability (IOV) for clearance satisfactorily described the pharmacokinetics. Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days). Weight had a positive influence on central volume but was insufficient to warrant dosage adjustments. The inter-individual variability (coefficient of variation, CV%) for CL/F and V1/F was 24.4% and 29.6%, respectively. The IOV for CL/F was 17.8%. The proportional residual error (CV%) for groups A and B was 11.5% and 19.5%, respectively, and the additive error standard deviation (SD) was 57 ng/ml and 149 ng/ml, respectively. CONCLUSION The typical parameter values were comparable with those estimated in much smaller cohorts of healthy subjects and in malaria patients treated with single-dose mefloquine. The lower unexplained variability in the blinded study suggested these subjects may have been more compliant in taking their medication than soldiers in the open-label study.
Collapse
Affiliation(s)
- B G Charles
- School of Pharmacy, The University of Queensland, Brisbane, 4072, QLD, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|